Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β

Gastroenterology

Volumn 119, Issue 5, 2000, Pages 1209-1218

  Schmid, Roland M ^a,b  

^a UNIVERSITY OF ULM   (Germany)

^b University of Dim   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CHUK PROTEIN, HUMAN; ENZYME INHIBITOR; GASTROINTESTINAL AGENT; I KAPPA B; I KAPPA B KINASE; IKBKB PROTEIN, HUMAN; IKBKE PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NF KAPPA B KINASE; NF-KAPPA B KINASE; PROTEIN SERINE THREONINE KINASE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL LINE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GENETIC TRANSCRIPTION; HUMAN; LEUKEMIA CELL LINE; METABOLISM; PH; PHOSPHORYLATION;

ADENOSINE TRIPHOSPHATE; CELL LINE; DRUG COMBINATIONS; ENZYME INHIBITORS; GASTROINTESTINAL AGENTS; HUMANS; HYDROGEN-ION CONCENTRATION; I-KAPPA B KINASE; I-KAPPA B PROTEINS; JURKAT CELLS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SULFASALAZINE; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034322370     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.19458     Document Type: Article

References (31)

1. Schottelius AJ, Baldwin AS Jr. A role for transcription factor NF-kappa B in intestinal inflammation. Int J Colorectal Dis 1999; 14:18-28.
2. Ghosh S, May MJ, Kopp EB. NF-xB and Rel proteins: evolutionary conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
3. Schmid RM, Adler G. NF-KB/Rel/lxB: implications in gastrointestinal diseases. Gastroenterology 2000:118:1208-1228.
4. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Schölmerich J, Gross V. Nuclear factor KB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;15:357-369.
5. Neurath MF, Pettersson S, Meyerzum Büschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonu-cleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat Med 1996;2:998-1004.
6. Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of kBa: a mechanism for NF-KB activation. Mol Cell Biol 1993:13:33013310.
7. Zandi E, Rothwarf DM, Delhase M, Hayakawa M, Karin M. The kB kinase complex (IKK) contains two kinase subunits, IKKa and IKK, necessary for kB phosphorylation and NF-KB activation. Cell 1997:91:243-252.
8. Hu Y, Baud V, Delhase M, Zhang P, Deerinck T, Ellisman M, Johnson R, Karin M. Abnormal morphogenesis but intact IKKb activation in mice lacking the IKKa subunit of kB kinase. Science 1999;284:316-320.
9. Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, Okumura K. Differential regulation of kB kinase a and b by two upstream kinases, NF-KB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sei U S A 1998:95:3537-3542.
10. Kopp EB, Ghosh S. Inhibition of NF-KB by sodium salicylate and aspirin. Science 1994:265:956-959.
11. Scheinman Rl, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS Jr. Characterization of mechanisms involved in transrepression of NF-KB by activated glucocorticoid receptors. Mol Cell Biol 1995:15:943-953.
12. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270: 286-290.
13. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998:101:1163-1174.
14. Hoffmeyer A, Avots A, Flory E, Weber CK, Serfling E, Rapp UR. The GABP-responsive element of the interleukin-2 enhancer is regulated by JNK/SAPK-activating pathways in T lymphocytes. J Biol Chem 1998:273:10112-10119.
15. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970:227:680-685.
16. Li J, Peet GW, Pullen SS, Schembri-King J, Warren TC, Marcu KB, Kehry MR, Barton R, Jakes S. Recombinant kB kinases a and are direct kinases of kBa. J Biol Chem 1998;273: 30736-30741.
17. Schild HO. Drug antagonism and pAx. Pharmacol Rev 1957;9: 242-246.
18. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, wu Li J, Young DB, Barbosa M, Mann M, Manning A, Rao A. IKK-1 and IKK-2: cytokine-activated kB kinases essential for NF-KB activation. Science 1997:278:860-866.
19. Shanahan F, Niederlehner A, Carramanzana N, Anton P. Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology 1990;20:217-224.
20. Yin M-J, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of kB kinase-. Nature 1998:396:77-80.
21. Peppercorn MA, Goldman P. Distribution studies of salicylazo-sulfapyridine and its metabolites. Gastroenterology 1973;64: 240-245.
22. Miagkov AV, Kovalenko DV, Brown CE, Didsbury JR, Cogswell JP, Stimpson SA, Baldwin AS, Makarov SS. NF-KB activation provides the potential link between inflammation and hyperplasia in the arthritic joint. Proc Natl Acad Sei U S A 1998;95:13859-13864.
23. Bondeson J, Foxwell B, Brennan F, Feldmann M. Defining therapeutic targets by using adenovirus: blocking NF-KB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators. Proc Natl Acad Sei USA 1999;96:5668-5673.
24. Bird HA. Sulphasalazine or sulphapyridine or 5-aminosalicylic acid which is the active moiety in rheumatoid arthritis. Br J Rheumatol 1995;34(suppl 2):16-19.
25. Farr A, Brodrick A, Bacon PA. Plasma synovial fluid concentration of sulphasalazine and two of its metabolites in rheumatoid arthritis. Rheumatol Int 1985:5:247-251.
26. Hanngren A, Hansson E, Svartz N, Ullberg S. Distribution and metabolism of salicyl-azo-sulfapyridine. II: a study with S35 salicyl-azo-sulfapyridine and S35-sulfapyridine. Acta Med Scand 1963:173:391-399.
27. Das KM, Dubin R. Clinical pharmacokinetics of sulfasalazine. Clin Pharmacokinet 1976:1:406-425.
28. Azad Kahn AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulfasalazine. Lancet 1977;2: 892-895.
29. Egan U, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, Lipsky JJ, McKean DJ. Inhibition of interleukin-1-stimulated NF-KB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999;274: 26448-26453.
30. Kaiser GC, Van F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor KB activation in mouse colonocytes. Gastroenterology 1999;116:602-609.
31. Van F, Polk DB. Aminosalicylic acid inhibits kB kinase alpha phosphorylation of IkappaBalpha in mouse intestinal epithelial cells. J Biol Chem 1999;274:36631-36636.